{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:18:59Z","timestamp":1779243539832,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The purpose of this study was to evaluate the incidence of vitreomacular adhesion (VMA) release after anti-VEGF therapy for the treatment of diabetic macular edema (DME) and to evaluate further changes in outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>\n This was a retrospective study that enrolled 66 eyes of 66 patients with DME who presented with VMA diagnosed by spectral-domain optical coherence tomography (OCT) at baseline. VMA was classified as focal (attachment: \u2264 1500\u00a0\u03bcm) or broad (attachment: &gt; 1500\u00a0\u03bcm). All patients received at least three monthly intravitreal injections of an anti-VEGF agent. Follow-up visits were performed 1 month after each injection to evaluate the incidence of VMA release.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean patient age was 61.4 years (range: 29 to 78 years), and 72.7\u2009% were male. The mean best-corrected visual acuity was 0.62 logMAR, and the mean central retinal thickness (CRT) was 473\u00a0\u03bcm at baseline. The mean length of follow-up was 18.5 months, and the mean number of injections was 5.8. The intravitreal drugs used were aflibercept (40.9\u2009%), ranibizumab (37.9\u2009%) and bevacizumab (21.2\u2009%). Forty-seven eyes had broad VMA, and 19 had focal VMA. Twenty-two eyes (33.3\u2009%) developed VMA release following a mean of 5.7 injections (range: 3\u201313). Sixteen eyes (72.7\u2009%) with focal VMA and 6 eyes (27.3\u2009%) with broad VMA at baseline developed VMA release. Twenty-one eyes that developed VMA release showed an improvement in CRT following VMA release (mean: -106\u00a0\u03bcm; range: 22 to 289\u00a0\u03bcm).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>VMA release occurs in approximately 1\/3 of patients with DME following anti-VEGF therapy. Most of them show a short-term decrease in CRT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-021-00295-8","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T19:03:44Z","timestamp":1616180624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Vitreomacular interface after anti-VEGF injections in diabetic macular edema"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8817-7200","authenticated-orcid":false,"given":"Carlos E.","family":"Veloso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel N.","family":"Brocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rcio B.","family":"Nehemy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"295_CR1","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","volume":"132","author":"R Varma","year":"2014","unstructured":"Varma R, Bressler NM, Doan QV, et al. Prevalence and risk factor for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132:1334\u201340.","journal-title":"JAMA Ophthalmol"},{"key":"295_CR2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","volume":"142","author":"QD Nguyen","year":"2006","unstructured":"Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961\u20139.","journal-title":"Am J Ophthalmol"},{"key":"295_CR3","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","volume":"116","author":"QD Nguyen","year":"2009","unstructured":"Nguyen QD, Shah SM, Heier JS, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009;116:2175\u201381.","journal-title":"Ophthalmology"},{"key":"295_CR4","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","volume":"117","author":"QD Nguyen","year":"2010","unstructured":"Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146\u201351.","journal-title":"Ophthalmology"},{"key":"295_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ophtha.2014.08.047","volume":"122","author":"MJ Elman","year":"2015","unstructured":"Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results. Ophthalmology. 2015;122:375\u201381.","journal-title":"Ophthalmology"},{"key":"295_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.6786","author":"SB Bressler","year":"2019","unstructured":"Bressler SB, Odia I, Maguire MG, et al. Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti-vascular endothelial growth factor therapy: an exploratory analysis of the protocol T randomized clinical trial. JAMA Ophthalmol. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.6786.","journal-title":"JAMA Ophthalmol Published online first: 24 Jan"},{"key":"295_CR7","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/bjophthalmol-2016-309747","volume":"101","author":"RP Singh","year":"2017","unstructured":"Singh RP, Habbu KA, Bedi R. A retrospective study of the influence of the vitreomacular interface on macular oedema secondary to retinal vein occlusion. Br J Ophthalmol. 2017;101:1340\u20135.","journal-title":"Br J Ophthalmol"},{"key":"295_CR8","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.ophtha.2013.05.032","volume":"120","author":"U Mayr-Sponer","year":"2013","unstructured":"Mayr-Sponer U, Waldstein SM, Kundi M, et al. Influence of vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related degeneration. Ophthalmology. 2013;120:2620\u20139.","journal-title":"Ophthalmology"},{"key":"295_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.ophtha.2015.02.031","volume":"122","author":"TA Ciulla","year":"2015","unstructured":"Ciulla TA, Ying GS, Maguire MG, et al. Influence of the vitreomacular interface on treatment outcomes in the comparison of age-related macular degeneration treatment trials. Ophthalmology. 2015;122:1203\u201311.","journal-title":"Ophthalmology"},{"key":"295_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000459626","volume":"58","author":"TCM Kanadani","year":"2017","unstructured":"Kanadani TCM, Dos Reis Veloso CE, Dorairaj S, et al. Influence of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. Ophthalmic Res. 2017;58:18\u201326.","journal-title":"Ophthalmic Res"},{"key":"295_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ophtha.2015.09.032","volume":"123","author":"MA Sadiq","year":"2016","unstructured":"Sadiq MA, Soliman MK, Sarwar S, et al. Effect of vitreomacular adhesion on treatment outcomes in the ranibizumab for edema of the macula in diabetes (READ-3) study. Ophthalmology. 2016;123:324\u20139.","journal-title":"Ophthalmology"},{"key":"295_CR12","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ophtha.2015.04.028","volume":"122","author":"CE Veloso","year":"2015","unstructured":"Veloso CE, Kanadani TM, Pereira FB, et al. Vitreomacular interface after anti-vascular endothelial growth factor injections in neovascular age-related macular degeneration. Ophthalmology. 2015;122:1569\u201372.","journal-title":"Ophthalmology"},{"key":"295_CR13","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1016\/j.ophtha.2013.07.042","volume":"120","author":"JS Duker","year":"2013","unstructured":"Duker JS, Kaiser PK, Binder S. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013;120:2611\u20139.","journal-title":"Ophthalmology"},{"key":"295_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2008.10.001","volume":"54","author":"N Bhagat","year":"2009","unstructured":"Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54:1\u201332.","journal-title":"Surv Ophthalmol"},{"key":"295_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0161-6420(97)30289-9","volume":"104","author":"T Hikichi","year":"1997","unstructured":"Hikichi T, Fujio N, Akiba J, et al. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology. 1997;104:473\u20138.","journal-title":"Ophthalmology"},{"key":"295_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ajo.2004.12.084","volume":"139","author":"D Gaucher","year":"2005","unstructured":"Gaucher D, Tadayoni R, Erginay A, et al. Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema. Am J Ophthalmol. 2005;139:807\u201313.","journal-title":"Am J Ophthalmol"},{"key":"295_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/IAE.0000000000001280","volume":"37","author":"TL Jackson","year":"2017","unstructured":"Jackson TL, Nicod E, Angelis A, et al. Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature. Retina. 2017;37:886\u201395.","journal-title":"Retina"},{"key":"295_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00417-016-3562-0","volume":"255","author":"Y Wong","year":"2017","unstructured":"Wong Y, Steel DHW, Habib MS, et al. Vitreoretinal interface abnormalities in patients treated with ranibizumab for diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol. 2017;255:733\u201342.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"295_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.ajo.2006.08.002","volume":"142","author":"JY Chuo","year":"2006","unstructured":"Chuo JY, Lee TYY, Hollands H, Morris AH, Reyes RC, Rossiter JD, Meredith SP, Maberley DAL. Risk factors for posterior vitreous detachment: a case-control study. Am J Ophthalmol. 2006;142:931\u20137.","journal-title":"Am J Ophthalmol"},{"key":"295_CR20","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.ophtha.2012.03.050","volume":"119","author":"T Hikichi","year":"2012","unstructured":"Hikichi T. Time course of development of posterior vitreous detachments after phacoemulsification surgery. Ophthalmology. 2012;119:2102\u20137.","journal-title":"Ophthalmology"},{"key":"295_CR21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s003470050054","volume":"93","author":"B Weber-Krause","year":"1996","unstructured":"Weber-Krause B, Eckardt U. Incidence of posterior vitreous detachment in eyes with and without age-related macular degeneration. An ultrasonic study. Ophthalmologe. 1996;93:660\u201365.","journal-title":"Ophthalmologe"},{"key":"295_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF02764282","volume":"228","author":"J Sebag","year":"1990","unstructured":"Sebag J, Buzney SM, Belyea DA, et al. Posterior vitreous detachment following panretinal laser photocoagulation. Graefes Arch Clin Exp Ophthalmol. 1990;228:5\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"295_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ajo.2008.09.026","volume":"147","author":"SJ Lee","year":"2009","unstructured":"Lee SJ, Lee CS, Koh HJ. Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study. Am J Ophthalmol. 2009;147:621\u20136.","journal-title":"Am J Ophthalmol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-021-00295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40942-021-00295-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-021-00295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T19:06:09Z","timestamp":1616180769000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-021-00295-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1186\/s40942-021-00295-8","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"11 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Federal University of Minas Gerais in Belo Horizonte, Brazil, approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All subjects were informed about the nature of the study and signed a written informed consent form in accordance with the tenets of The Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}